No abstract

BackgroundEliminating mother-to-child transmission (MTCT) of HIV, hepatitis B, and syphilis is a challenge in Brazil. Many policies have been implemented since 1986, but important gaps remain. This study aimed to describe the trends of MTCT in Brazil and evaluate the gaps and perspectives in this scenario.MethodsThis is a descriptive study conducted with secondary data publicly available in the information systems of the Brazilian Ministry of Health regarding data on HIV, syphilis, and hepatitis B in pregnant women and children from 2011 to 2021.ResultsHIV and hepatitis B have had constant rates over the years in pregnant women, with the detection rates around 0.5/1,000 live birth (LB) and 2.5/1.000LB, respectively. The same did not happen with syphilis, which has shown an increasing line in the last decade. In 2011, the detection rate of syphilis in pregnancy was 4.7/1,000LB, and in 2021 it reached 27.1/1,000LB. Regarding the trends in children, an important decrease was observed in HIV/AIDS (incidence rate from 0.17/1,000 in 2011 to 0.04/1,000 in 2021) and Hepatitis B (incidence rate from 0.9/1,000LB in 2011 to 0.5/1,000LB in 2021). For congenital syphilis, there is a continuous increase, being 3.3/1,000LB in 2011 and 9.9/1,000LB in 2021. Data from the HIV clinical monitoring showed that antiretroviral treatment coverage among pregnant women identified increased slightly between 2011 and 2021, in Brazil, from 92.3% to 94.3%. For syphilis, 82.5% of pregnant women were treated with benzathine penicillin, and 88.7% in 2011. The historical series of hepatitis B vaccination coverage in children has decreased over the years; it was 96% in 2013 and 76% in 2021.ConclusionThese data show many gaps and some perspectives in the MTCT program in Brazil. The country is close to reaching MTCT HIV elimination, but there are many challenges regarding HBV and syphilis. These data can be used to organize the strategies to improve the Brazilian response to MTCT elimination of HIV, hepatitis B, and syphilis.

Background: The current need for pulmonary mechanical ventilation related to COVID-19 exceeds the ability of health systems worldwide to acquire and produce mechanical ventilators. The major cause of mortality in patients with this disease is hypoxemia secondary to an inflammatory storm in the lungs associated with thrombotic events. A partnership was established between the university and the private engineering and industrial automation sector to concept and design novel a low-cost emergency mechanical ventilator that could be rapidly available for use in emergency, transport or low-resource health care system, and attend the urgent demand of artificial respiratory system that is need worldwide. It was evaluated the viability of oxygenation and pulmonary ventilation with an emergency mechanical ventilation device called 10D-EMV in animal experiments. A two-stage sequential adaptive study was conducted in 10 sheep, divided into group I (PEEP valve close to the device) and group II (PEEP valve distal to the device). Each animal underwent mechanical ventilation for a total of 120 minutes. Results: The mean oxygenation in group I and group II were 368 mmHg and 366 mmHg, respectively, while the mean partial pressure of carbon dioxide was 58 mmHg and 48 mmHg. Conclusion: This study demonstrates the viability of the 10D device as a novel proposed emergency mechanical ventilator, in order to attend the pandemics demand. Further clinical studies in humans are needed to assess its safety and efficacy.